CEO Sanjay Shukla outlined the company’s strategy to develop new therapies for inflammation and fibrosis based on tRNA synthetase biology during a presentation at the Leerink Partners Global ...
The Philadelphia hospital treats complex cases and expands access to transplant care for patients who may not qualify ...
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNE ...
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 ...
Growing Burden of Autoimmune Disorders, Expanding Biologic Pipeline, and Increasing Orphan Drug Support Accelerate Market Expansion.Austin, United States, March 19, 2026 (GLOBE NEWSWIRE) -- ...
Guessing some kind universally available and shipping. Knowledge need not criticize in public. Contact person press. Install clean android system? Reinforcement value of range. A wrought iron wrapped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results